XP Director Exited at $19 Before Lula's Rout to $14
An XP Inc. director sold $2.41M at $19.58 six days after a prospectus filing; the stock has since fallen to $14.56 on post-Lula repricing, trading at 1.2x forward earnings. The company beat consensus
XP Director Exited at $19 Before Lula's Rout to $14
NEW YORK, November 4 —
An XP Inc. (XP) director sold $2.41 million of stock six days after the company filed a 424B7 prospectus supplement with the SEC; the shares have since fallen from his $19.58 exit to $14.56 on three post-Lula bank downgrades, leaving a 1.2x forward P/E against a $24.67 consensus target with zero insider buying in the intervening period.
- Director Dos Santos sold 123,257 XP shares at $19.58 on September 16, six days after a 424B7 SEC prospectus filing.
- XP shares currently trade at $14.56, down $5.02 from the director's exit price, on a 1.2x forward P/E multiple.
- Consensus analyst target is $24.67, $10.11 above the current price; Morgan Stanley set a $19 floor on October 29.
A Sale Timed to the Prospectus Window
XP Inc. distributes brokerage, fixed income, mutual funds, derivatives, credit cards, insurance, and wealth management through online portals and an omni-channel network, serving retail, high-net-worth, and institutional clients in Brazil. Director Dos Santos Bruno Constantino Alexandre sold 123,257 shares for total proceeds of $2,413,865, per his Form 4 filing, on September 16. The transaction came six days after XP filed a 424B7 prospectus supplement with the SEC. No other insider transaction appears in the 90-day record: $0 purchased, $2.41 million sold. The prospectus window and the director's exit share a six-day gap, a sequence that institutional holders now weigh alongside the earnings record.
The Selloff Priced Politics, Not Margins
The post-Lula repricing that sent XP shares down 10% in a week stripped the premium from a business generating 69.2% gross margins on $18.63 billion in trailing revenue. The business is a financial distribution layer serving institutional traders, high-net-worth clients, and retail investors across dozens of product categories, with no inventory and recurring revenue from managed assets. Three bank downgrades compressed the multiple to 1.2x forward earnings. Morgan Stanley, the most recently disclosed bearish major bank, set a $19 target on October 29, still $4.44 above the current price, and XP's latest fundamentals show the consensus spread runs even wider.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| XP | $7.4B | 5.9x | -21.4% |
| PAGS | $2.1B | 4.0x | -20.6% |
| ITUB | $77.7B | 7.3x | -2.9% |
| SUZ | $11.4B | 6.3x | +1.2% |
| INTR | $1.7B | 4.2x | -59.3% |
| PGNY | $2.2B | 12.6x | +53.9% |
Three Beats in Four Quarters, With One More Due
XP has beaten consensus EPS estimates in three of its last four reported quarters, most recently by 1.9% ($2.67 actual against $2.62 estimated), a track record that keeps the fundamental case open even as the stock sits below every disclosed analyst price target. ARGA Investment Management purchased XP shares as of November 4, one signal that the selloff has drawn institutional buyers. The next quarterly EPS print is the number that matters: a continued beat streak against a consensus now pricing in Brazilian political risk would put the $24.67 mean target back in frame. Run the free XP Inc. deep-dive to follow the fundamentals in real time.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
When did XP Inc. director sell stock and why?
Director Bruno Constantino Alexandre sold 123,257 shares at $19.58 on September 16, six days after XP filed a 424B7 prospectus supplement with the SEC. Institutional holders now weigh this six-day gap between the prospectus filing and the sale alongside the earnings record.
Why has XP stock fallen from $19.58 to $14.56?
The post-Lula repricing sent XP shares down 10% in a week, stripping the premium from the business. Three bank downgrades, led by Morgan Stanley's $19 floor set on October 29, compressed the multiple to 1.2x forward earnings.
What is consensus seeing for XP valuation?
Consensus analyst target is $24.67, $10.11 above the current $14.56 price. Morgan Stanley set a $19 floor on October 29, still $4.44 above the current price, as three bank downgrades compressed the multiple to 1.2x forward earnings.
Has XP beaten earnings recently?
XP has beaten consensus EPS estimates in three of its last four reported quarters, most recently by 1.9%, posting $2.67 actual versus $2.62 estimated. This track record keeps the fundamental case open despite the stock trading below all disclosed analyst price targets.
Who is buying XP on the dip?
ARGA Investment Management purchased XP shares as of November 4, one signal that the selloff has drawn institutional buyers. No other insider transaction appears in the 90-day record: $0 purchased, $2.41 million sold.
An XP Inc. director sold $2.41M of stock at $19.58 in mid-September — days after the company filed a prospectus supplement — and the shares have since fallen to $14.56 following three broker downgrades triggered by Lula's election win. With a forward P/E of 1.2x and three beats in the last four quarters, the question is whether the insider read the political risk correctly or the selloff has pushed a profitable platform into deep-value territory.
Sources & Filings